AstraZeneca plc (ADR)

+$0.02 (+0.0%)
Closing price June 18, 2021
The race for finding the COVID-19 vaccine is in full swing, and it has just seen one team move ahead of the others. Before getting into an actual prediction basis for knowing which vaccine (or...
America and the rest of the world is getting ready for a vaccine that will help protect public health against the COVID-19 pandemic. The societal impact of the coronavirus has changed many lives, and...
Three U.S. COVID-19 vaccine trials are now in Phase 3 studies. All three appear to have some serious benefits, but none are approved yet.
Earnings season is in full swing, and we have put together a preview of some of the world’s largest players in the health care sector reporting this coming week.
Here is a look of a few of the biggest clinical trial and FDA updates to watch for in July 2020.
Amarin Corp. PLC (NASDAQ: AMRN) plans to mount a vigorous and speedy appeal of a U.S. District Court ruling that blocked its patents on the medication Vascepa, the company’s chief executive says....
Until late Monday, Amarin continued to get good news relevant to Vascepa, its treatment for cardiovascular disease. The big news, though, was lurking in Nevada federal district court.
Some investors are looking for conservative growth ideas, and big pharma may be the ticket. These four top stocks have been hit hard, and the companies have paid dependable dividends for years.
24/7 Wall St. screened the Merrill Lynch health care research database looking for large pharmaceutical leaders that also pay solid and dependable dividends. These five make sense for growth and...
When companies see their shares rise by 100% or more in a single day, it's usually because of a buyout or an extremely positive change in a company's future prospects. For Genprex, it was a nod from...
AstraZeneca has announced that the FDA has approved its companion diagnostic test that identifies patients with metastatic pancreatic cancer.
The top analyst upgrades, downgrades and initiations for Wednesday included Acorda Therapeutics, Activision Blizzard, Bloom Energy,, CBS, Deere and Ferrari.
Inovio Pharmaceuticals shares dipped on Wednesday after it was announced that the firm’s partnership with AstraZeneca would be scaled back.
The top analyst upgrades, downgrades and initiations seen on Tuesday included Alcoa, Broadcom, Dow, Lyft, Netflix, Roku, Walt Disney, Wingstop and Xilinx.
The top analyst upgrades, downgrades and initiations seen on Monday included, CarMax, Celgene, Chevron, Exxon Mobil, Lyft, FedEx, Peabody Energy, UPS and Wells Fargo.